Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on December 13, 2022, covering events occurring on December 8, 2022. The filing primarily addresses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Base Salary: Not less than $450,000 annually.
- Target Cash Bonus: 40% of base salary.
- Initial Stock Options: 500,000 shares of Class A common stock.
- Performance Equity: Potential grant of 0.6% of outstanding shares upon completion of $50 million in financing over 12 months.
- Severance: Nine months of base salary plus COBRA coverage and prorated bonus upon termination without cause or resignation for good reason.
Material Changes
The material change reported is the appointment of Steven Tuch as Chief Financial Officer, effective December 8, 2022. Mr. Tuch brings over 20 years of experience in financial and business development within the life sciences sector, including prior roles at Rallybio Corporation, BMO Capital Markets, and Deutsche Bank Securities.
Outlook, Risks, and Unusual Items
Management Commentary: The appointment is intended to leverage Mr. Tuch's extensive background in equity capital markets and corporate development to support the company's growth and financing efforts.
Contingencies: The Performance Equity grant is contingent upon the successful completion of a financing or series of financings totaling at least $50 million within a 12-month period.
Risks: The employment agreement includes standard restrictive covenants, including a nine-month post-employment non-compete and a one-year non-solicit provision.
Investor Verification Checklist
- Verify the vesting schedule for the 500,000 initial stock options (33.33% on first anniversary, remainder quarterly over two years).
- Confirm the specific conditions and timeline for the potential 0.6% Performance Equity grant tied to the $50 million financing target.
- Review the full text of the Tuch Employment Agreement (Exhibit 10.1) for detailed definitions of "cause" and "good reason" regarding severance eligibility.
- Check subsequent filings to determine if the $50 million financing target was met to trigger the Performance Equity grant.